Member Info for WeTookPelham

https://twitter.com/GlencrossJohn/status/1017385368381992961

Are we any to the wiser about this? An LSE glitch?

Showing as delayed?

...Just to add..your comment "...we are suddenly linked to a $100b plus company possibly on both platforms".
That is something us laymen and newbies can definitely all understand :)
(Hence yet another reason for a cheeky little top up by myself at these potentially bargain basement prices)

Thanks for your answer Inanaco.

For us layman, can some explain in simple terms what they think is going with regards with Scancell and Genetechs TECENTRIQ(ATEZOLIZUMAB) trial?

...???

Is this out yet then? Can't find it myself.

...just for a second Recent tweet - what are Scancell implying with this? That there's room for one more billion pound biotech at the Oxford Tech Park perhaps? ;) https://twitter.com/OxfordshireLEP/status/1006531963501637632

Does the round figure I.e. 50k indicate institutional buyers?

We had an RNS when we had a '1' trade. Are we thinking the same thing this time?

...and isn't the purpose of the presentation/meeting about "partnering"?

Presenting or their own or with another party? Is that a pertinent question?

Crumbs thanks for that link you sent... but something very odd about the details, no? "Scancell Holdings Ltd - 1:30 PM�1:45 PM Jun 5, 2018 - Theater 1, Level 0" "Description: Partnering. Session ID: 21878" "Who's Attending (6)" So... only 15 minutes long, and about "partnering"? Mmm... the plot thickens lol.

...more mainstream press. Currently the main headline on the BBC website: http://www.bbc.co.uk/news/health-44343415

Does somebody know something that's happening at ASCO perhaps???

https://twitter.com/scancellpharma @scancellpharma 24h24 hours ago More SCANCELL Retweeted Alexey Bersenev A role for #moditope CD4+ T cells? SCANCELL Retweeted David Crow ‏@bydavidcrow May 30 Merck signals it will be more cautious with combo trials after Incyte failure (needs single-agent activity for both drugs), but AstraZeneca says risk still worth taking. #ASCO18 $MRK $AZN SCANCELL Retweeted @GlencrossJohn May 30 John Glencross Retweeted bermudashorts2 V interesting article @bydavidcrow that cancer combo drug trials fail because each drug hasn't shown activity or efficacy as monotherapy. Re @scancellpharma upcoming combo trial of SCIB1 & Keytruda, noted both SCIB1 & Keytruda have shown evidence of effectiveness as monotherapies

https://twitter.com/scancellpharma

Believer even*

Lol...I was always a believe too ;)